Pulse Biosciences (NASDAQ:PLSE) Trading Down 7.8% – What’s Next?

Pulse Biosciences, Inc. (NASDAQ:PLSE)’s stock price was down 7.8% during trading on Wednesday . The stock traded as low as $20.46 and last traded at $20.18. Approximately 125,583 shares were traded during trading, a decline of 16% from the average daily volume of 149,235 shares. The stock had previously closed at $21.89.

Analyst Upgrades and Downgrades

Separately, StockNews.com raised shares of Pulse Biosciences to a “sell” rating in a report on Thursday, January 2nd.

Pulse Biosciences Price Performance

The stock has a 50-day moving average of $19.33 and a 200-day moving average of $18.31.

Insider Buying and Selling at Pulse Biosciences

In related news, Director Robert W. Duggan purchased 55,256 shares of the firm’s stock in a transaction dated Friday, December 13th. The shares were purchased at an average price of $17.18 per share, with a total value of $949,298.08. Following the acquisition, the director now directly owns 42,328,717 shares of the company’s stock, valued at approximately $727,207,358.06. This represents a 0.13 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Burke Thomas Barrett sold 50,000 shares of Pulse Biosciences stock in a transaction on Wednesday, December 11th. The stock was sold at an average price of $17.42, for a total transaction of $871,000.00. Following the sale, the chief executive officer now directly owns 63,172 shares of the company’s stock, valued at $1,100,456.24. This represents a 44.18 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 71.50% of the company’s stock.

Hedge Funds Weigh In On Pulse Biosciences

A number of hedge funds and other institutional investors have recently modified their holdings of the company. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC bought a new stake in Pulse Biosciences in the third quarter worth $588,000. Charles Schwab Investment Management Inc. increased its position in shares of Pulse Biosciences by 193.0% in the third quarter. Charles Schwab Investment Management Inc. now owns 148,114 shares of the company’s stock valued at $2,598,000 after acquiring an additional 97,565 shares during the period. State Street Corp increased its position in shares of Pulse Biosciences by 17.8% in the third quarter. State Street Corp now owns 461,333 shares of the company’s stock valued at $8,092,000 after acquiring an additional 69,696 shares during the period. Geode Capital Management LLC raised its stake in shares of Pulse Biosciences by 7.8% during the third quarter. Geode Capital Management LLC now owns 457,165 shares of the company’s stock valued at $8,020,000 after acquiring an additional 33,200 shares during the last quarter. Finally, Franklin Resources Inc. purchased a new position in Pulse Biosciences during the 3rd quarter valued at about $378,000. 76.95% of the stock is currently owned by hedge funds and other institutional investors.

About Pulse Biosciences

Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.